Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Public ClinicalTrials.gov record NCT05928806. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Study identification
- NCT ID
- NCT05928806
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Michael B. Atkins, MD
- Other
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- Balstilimab Drug
- Botensilimab Drug
- Ipilimumab Drug
- Nivolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 24, 2023
- Primary completion
- Nov 9, 2026
- Completion
- Nov 9, 2027
- Last update posted
- Feb 10, 2026
2023 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego | La Jolla | California | 92093 | — |
| Yale University, Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20057 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | Indiana | 46202 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber - Partners Cancer Care, Inc | Boston | Massachusetts | 02215 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Cornell University | Ithaca | New York | 14850 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Penn Medicine Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05928806, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2026 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05928806 live on ClinicalTrials.gov.